pfizer se redresse en redressant

http://www.pharmalot.com/2008/12/pfizer-buys-rights-to-a-drug-to-fix-a-curved-penis/

Pfizer Buys Rights To A Drug To Fix A Curved Penis
30 Comments

By Ed Silverman // December 18th, 2008 // 6:46 am

Yes, the drugmaker will spend $75 million upfront and up to $410 million to buy the rights from Auxilium Pharmaceuticals to develop an experimental med for combating Peyronie’s disease, in which the buildup of collagen on the shaft of the penis reduces flexibility and makes intercourse uncomfortable. This afflicts an estimated 1 percent of men, according to the National Institutes of Health.

The injectable drug, known as Xiaflex, is also being investigated to treat Dupuytren’s contracture, which is the growth of collagen in the palm of the hand impairs the use of the fingers and is found in an estimated an 3 percent of whites, often of Northern European ancestry. The drug is also being tested for Frozen Shoulder syndrome, or Adhesive Capsulitis (see statement).

Lol >>

je cherche la phase ; pré-liminaire , phase-1, 2 , ou la finale . C'est pour savoir combien Pfizer est prêt à payer pour ça .

Ps ; j'ai un principe de base ; jamais payer pour ça , lol

C'est une phase 2 b , je cherche le CA potentiel ..

Auxilium has completed Phase III trials for XIAFLEX in Dupuytren's contracture and expects to file a U.S. biologics license application (BLA) for the treatment of Dupuytren's contracture with the U.S. Food and Drug Administration in early 2009. Pfizer expects to file XIAFLEX for approval for the treatment of Dupuytren's contracture in Europe in 2010. XIAFLEX is also being evaluated in a Phase IIb trial for Peyronie's disease with top line data expected in late 2009.

"Today, Pfizer and Auxilium have forged a compelling partnership and together we believe we have the opportunity to offer the first, effective non-surgical treatment for two diseases," said Armando Anido, Chief Executive Officer and President of Auxilium. "With the strength of Pfizer's commercialization and development organization, this relationship greatly enhances our ability to effectively introduce this potentially groundbreaking technology for the treatment of Dupuytren's contracture and Peyronie's disease in Europe."

Under the agreement, Pfizer will make an up-front payment of $75 million to Auxilium and up to $410 million in potential milestone payments, with $150 million tied to regulatory milestones and $260 million based on sales milestones. Auxilium will receive increasing tiered royalties based on sales of XIAFLEX in Pfizer's territories

Très intéressant >>

Phase 2 b pour l'une des indications et phase 3 terminée pour l'autre et pour le CA potentiel, on trouve ceci ;

"We believe there are approximately 450,000 potential patients annually in U.S. and EU for Dupuytren’s & Peyronie’s indications - > $1 Billion opportunity, based on market research and analysis "

selon Auxilium Pharmaceuticals ; on peut donc faire le comparatif avec le Napro

merci djerbi pour ta recherche

il faudrait voir ça de près(si j'ose dire lol) mais je pense que le marché du napro est plus concurrentiel et surtout a plus de chance d'évoluer en terme quantitatif que le marché du P. de travers lol de lol

Il faut considérer aussi que Auxilium est une boîte qui brûle 40M$ par an et qui ne les avait plus fin décembre ( donc moins d'1 an de cash )...
Donc Pfizer et les autres prétendants aux produits n'ont pas dû faire de trop gros chèques, mais juste assez pour convaincre les gens d'auxilium qui trouvent là le moyen de se financer 1 an et demi de +.

Ce qui n'est pas le cas de Nicox qui avec ses 100M€ ( + les potentiels milestones et upfronts ) a largement de quoi se financer de manière autonome. L'AK de 2007 semble de ce point de vue une excellente chose.

Après le Viagra, ce sont des spécialistes !!!